Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 131.22% | 331.67% | 693.85% | 742.51% | 242.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 131.22% | 331.67% | 693.85% | 742.51% | 242.98% |
| Cost of Revenue | -5.03% | 139.92% | -17.12% | 33.11% | 36.68% |
| Gross Profit | 157.04% | -34.63% | 51.33% | 155.85% | 18.21% |
| SG&A Expenses | 7.08% | -18.64% | 13.55% | 5.82% | 22.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.19% | 59.47% | 66.23% | 23.02% | 31.82% |
| Operating Income | 75.70% | -1.88% | 13.16% | 86.97% | 2.10% |
| Income Before Tax | 59.78% | 28.16% | 179.13% | -16.17% | -13.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.78% | 28.16% | 179.13% | -16.17% | -13.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.78% | 28.16% | 179.13% | -16.17% | -13.78% |
| EBIT | 75.70% | -1.88% | 13.16% | 86.97% | 2.10% |
| EBITDA | 77.40% | -3.10% | 13.13% | 88.98% | 1.71% |
| EPS Basic | 85.72% | 33.72% | 180.68% | -42.25% | 48.15% |
| Normalized Basic EPS | 85.72% | 33.72% | 180.68% | -41.83% | 48.04% |
| EPS Diluted | 85.72% | 33.72% | 180.68% | -42.25% | 48.15% |
| Normalized Diluted EPS | 85.72% | 33.72% | 180.68% | -41.83% | 48.04% |
| Average Basic Shares Outstanding | 181.67% | 8.37% | -1.93% | -18.33% | 119.44% |
| Average Diluted Shares Outstanding | 181.67% | 8.37% | -1.93% | -18.33% | 119.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |